Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

Tepezza’s dosage for thyroid eye disease (TED) is based on your body weight. Your dosing schedule may vary based on factors such as your symptoms and other medications you take. Tepezza is a ...

DEAR DR. ROACH: I had a total thyroidectomy in July 2022 for Graves’ disease. All the time leading up to this and almost all the time since, I’ve only had one short “active” period of thyroid eye ...

NEW ORLEANS — Teprotumumab (Tepezza) works equally well in both older and younger patients with thyroid eye disease (TED) and regardless of TED duration, new data suggest. TED is an autoimmune disease ...

Please provide your email address to receive an email when new articles are posted on . Ophthalmologists are a critical part of the medical team needed to treat thyroid eye disease. An endocrinologist ...

Tepezza (teprotumumab-trbw) is usually given as an infusion into your vein once every 3 weeks. A full course of treatment is 8 infusions, which takes about 5 months to complete. Tepezza’s dose is ...

Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? In the second quarter, Tepezza generated $479 ...